๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CD180 CART CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Autologous CAR19 T lymphocytes VHAG in Treating R/R T-ALL/LBL NCT06742463Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CD5-targeted CAR-T cells CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT07328503Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site๐Ÿ“ Riyadh King Faisal Specialist Hospital & Research Center ยท Tests: CAR T cells chimeric antigen receptor cells Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site๐Ÿ“ Los Angeles Joshua Sasine, MD, PhD ยท Tests: autologous hematopoietic stem cells added to planned CAR T A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) NCT06207123Phase 1, Phase 22 sites๐Ÿ“ Chicago๐Ÿ“ Rochester University of Chicago ยท Tests: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: CAR-T MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia NCT07371403NA1 site๐Ÿ“ Amman King Hussein Cancer Center ยท Tests: MB-CART19.1 A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies NCT06528301Phase 19 sites๐Ÿ“ Duarte๐Ÿ“ Chicago๐Ÿ“ Grand Rapids Umoja Biopharma ยท Tests: UB-VV111, rapamycin Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies NCT06227026Phase 11 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Anti-CD19 CAR-T cells Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ฮถ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) NCT03938987Phase 1, Phase 26 sites๐Ÿ“ Calgary๐Ÿ“ Calgary๐Ÿ“ Calgary University of Alberta ยท Tests: autologous CD19-directed chimeric antigen receptor (CAR) T-cells Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies NCT07312630EARLY Phase 11 site๐Ÿ“ Hefei PersonGen BioTherapeutics (Suzhou) Co., Ltd. ยท Tests: LV009 Injection Infusion HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCT04223765Phase 11 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) NCT06561074Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Decitabine, Venetoclax, Calaspargase pegol-mknl Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL NCT03937544Phase 2, Phase 31 site๐Ÿ“ Bandar Tun Razak National University of Malaysia ยท Tests: CD19 CAR-T CELLS, Cyclophosphamide, Fludarabine CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia NCT05043571Phase 11 site๐Ÿ“ Singapore National University Hospital, Singapore ยท Tests: CAR T-cell therapy A Study of CTD402 in T-ALL/LBL Patients NCT07070219Phase 1, Phase 29 sites๐Ÿ“ Palo Alto๐Ÿ“ Denver๐Ÿ“ Chicago Imviva Bio ยท Tests: CTD402 CAR T Cell Injection Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658Phase 22 sites๐Ÿ“ Tianjin๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: JAK1 Inhibitor TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT06481735Phase 1, Phase 26 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: supCD7 CART cells A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies NCT04532203EARLY Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: CAR-T cells, Ommaya Reservoir Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma NCT07388563Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: azacitidine, abatacept Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD19/CD22-CAR T cells Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients NCT06343090NA1 site๐Ÿ“ Beijing Beijing GoBroad Hospital ยท Tests: CD19 CAR T-cell, CD22 CAR T cells, hematopoietic stem-cell transplantation
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy